CD4(+)CD25(+) T cells facilitate the induction of T cell anergy

J Immunol. 2001 Oct 15;167(8):4271-5. doi: 10.4049/jimmunol.167.8.4271.

Abstract

T cell anergy is characterized by the inability of the T cell to produce IL-2 and proliferate. It is reversible by the addition of exogenous IL-2. A similar state of unresponsiveness is observed when the proliferative response of murine CD4(+)CD25(-) T cells is suppressed in vitro by coactivated CD4(+)CD25(+) T cells. We have developed a suppression system that uses beads coated with anti-CD3 and anti-CD28 Abs as surrogate APCs to study the interaction of CD4(+)CD25(+) and CD4(+)CD25(-) T cells in vitro. CD4(+)CD25(+) T cell-induced suppression, in this model, was not abrogated by blocking the B7-CTLA-4 pathway. When the CD4(+)CD25(-) T cells were separated from the CD4(+)CD25(+) suppressor cells after 24 h of coactivation by the Ab-coated beads, the CD4(+)CD25(-) T cells were unable to proliferate or to produce IL-2 upon restimulation. The induction of this anergic phenotype in the CD4(+)CD25(-) T cells correlated with the up-regulated expression of the gene related to anergy in lymphocytes (GRAIL), a novel anergy-related gene that acts as a negative regulator of IL-2 transcription. This system constitutes a novel mechanism of anergy induction in the presence of costimulation.

MeSH terms

  • Abatacept
  • Animals
  • Antigen-Presenting Cells
  • Antigens, CD
  • Antigens, Differentiation
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology*
  • CTLA-4 Antigen
  • Clonal Anergy / immunology*
  • Coculture Techniques
  • Immunoconjugates*
  • Interleukin-2 / pharmacology
  • Lymphocyte Activation
  • Mice
  • Mice, Inbred DBA
  • Receptors, Interleukin-2 / immunology*
  • Signal Transduction
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology*

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Immunoconjugates
  • Interleukin-2
  • Receptors, Interleukin-2
  • Abatacept